论文部分内容阅读
１９９９年１１月１日，生化制药公司（ＢｉｏＣｈｅｍＰｈａｒｍａＩｎｃ－）所推出的Ｚｅｆｆｉｘ得到了台湾卫生管理部门的认可。Ｚｅｆｆｉｘ（Ｌａｍｉｖｕｄｉｎｅ）是治疗慢性乙肝的首推新药物。Ｚｅｆｆｉｘ适用于年满１６岁以上，患有慢性乙肝且有明显病毒复制迹象的
On November 1, 1999, Zeffix from BioChemPharmaInc- was approved by Taiwan’s health authorities. Zeffix (Lamivudine) is the first of its kind to treat chronic hepatitis B. Zeffix for over 16 years of age, with chronic hepatitis B and obvious signs of viral replication